Skip to content

Psychedelic Microdosing: Prevalence and Subjective Effects

Lindsay P. Cameron, Angela Nazarian, David E. Olson

Journal of Psychoactive Drugs January 23, 2020 DOI: 10.1080/02791072.2020.1718250 via OpenAlex

Summary

AI-generated from the abstract

A survey of 2,347 people found that psychedelic microdosing—taking sub-hallucinogenic doses on a chronic schedule—is relatively common, with 17% of respondents having tried it. Microdosers reported that the practice subjectively improved their mood, decreased anxiety, and enhanced memory, attention, and sociability. The most common reasons for quitting were the risks of taking an illegal substance (24.28%) and difficulty obtaining psychedelic compounds (22.63%). The findings suggest microdosing is associated with a broad range of self-reported socio-affective, cognitive, and physical outcomes.

Study at a glance

Characteristics Cross-sectional survey Peer reviewed
Sample size 2,347
Population Anonymous online survey respondents
Keywords Psychology Traditional medicine
Citations 112
Key finding Psychedelic microdosing is relatively common and subjectively associated with improved mood, decreased anxiety, and enhanced memory, attention, and sociability.

Abstract

Anecdotal reports suggest that the administration of sub-hallucinogenic doses of psychedelic compounds on a chronic, intermittent schedule – a practice known as psychedelic microdosing – is becoming increasingly popular among young adults due to its purported ability to reduce symptoms of depression and anxiety while improving cognitive function and promoting social interaction. Using an anonymous online survey, we collected data from 2347 people to 1) assess the prevalence of psychedelic microdosing and characterize the demographics of microdosers, 2) determine whether microdosers associate the practice with changes in mood, cognitive function, social interaction, or physiology, and 3) investigate frequent motives for discontinuing the practice. Fifty-nine percent of respondents (NT = 2183) reported familiarity with the concept of psychedelic microdosing, with 17% (383 respondents, NT = 2200) having engaged in this practice. Microdosers attributed psychedelic microdosing with improving their mood, decreasing their anxiety, and enhancing their memory, attention, and sociability. The most frequently cited reasons for quitting microdosing (NT = 243) were the risks associated with taking an illegal substance (24.28%) and the difficulty of obtaining psychedelic compounds (22.63%). Overall, our findings suggest that psychedelic microdosing is relatively common and is subjectively associated with a broad spectrum of socio-affective, cognitive, and physical outcomes.

Comments

No comments yet.

Log in to comment